3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
18
Breast Neoplasms
16
Lung Neoplasms
10
Carcinoma, Non-Small-Cell Lung
6
Prostatic Neoplasms
5
Melanoma
5
Colorectal Neoplasms
5
Brain Neoplasms
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Skin Neoplasms
3
Myeloproliferative Disorders
3
Leukemia, Myeloid, Acute
3
Kidney Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Hepatocellular
3
Recurrence
2
Neoplasm, Residual
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Lung Diseases
2
Glioma
2
Glioblastoma
2
Genetic Predisposition to Disease
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Interventions
olaparib
3
enzalutamide
2
darolutamide
2
Prednisone
2
Prednisolone
2
Pluvicto
2
Docetaxel
2
Androgen Antagonists
2
Abiraterone Acetate
2
testosterone 17 beta-cypionate
1
radium Ra 223 dichloride
1
fludarabine phosphate
1
fludarabine
1
cabazitaxel
1
alovudine
1
abiraterone
1
Standard of Care
1
Radium-223
1
PSMA-617
1
Nivolumab
1
Gonadotropin-Releasing Hormone
1
Cyclophosphamide
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer
×
Blood Specimen Collection
×
90 days
×
Clear all
NCT06492122
2026-05-26
ProTACT
Full-Life Technologies GmbH
Phase 1
Recruiting
50 enrolled